TWI BIOTECHNOLOGY, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.9 TWD | -1.15% |
|
+2.38% | -7.86% |
| 2023 | TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | TWi Biotechnology, Inc. Exploring Promising Treatment for Granuloma Annulare (Ga) | CI |
| Sales 2021 | 66.4M 2.06M 163M | Sales 2022 | - | Capitalization | 1.01B 31.2M 2.47B |
|---|---|---|---|---|---|
| Net income 2021 | -15M -465K -36.85M | Net income 2022 | -76M -2.35M -187M | EV / Sales 2021 | 13.1 x |
| Net cash position 2021 | 219M 6.79M 538M | Net cash position 2022 | 158M 4.89M 388M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-70.2
x | P/E ratio 2022 |
-13.1
x | Employees | 19 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 77.35% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.15% | ||
| 1 week | +2.38% | ||
| Current month | +7.05% | ||
| 1 month | +0.39% | ||
| 3 months | -7.19% | ||
| 6 months | -14.29% | ||
| Current year | -7.86% |
1 week
12.30
13.35
1 month
11.1513.35
Current year
11.1514.95
1 year
11.1521.30
3 years
10.0026.00
5 years
5.1932.70
10 years
5.1994.00
| Managers | Title | Age | Since |
|---|---|---|---|
Chu Chun Weng
CEO | Chief Executive Officer | - | - |
Lien I Ho
DFI | Director of Finance/CFO | - | - |
Kuang Wei Lu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Yan Chang
BRD | Director/Board Member | - | 15/08/21 |
Jonas Wang
BRD | Director/Board Member | - | 04/06/19 |
Yi Chun Wu
CHM | Chairman | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/05/24 | 12.9 | -1.15% | 180,349 |
| 13/05/24 | 13.05 | +3.16% | 351,624 |
| 10/05/24 | 12.65 | +2.43% | 131,131 |
| 09/05/24 | 12.35 | -3.52% | 137,405 |
| 08/05/24 | 12.8 | +1.59% | 157,766 |
End-of-day quote Taipei Exchange, May 13, 2024
More quotes
TWi Biotechnology, Inc. is a Taiwan-based clinical stage biopharmaceutical company specializing in the development of new drugs for unmet medical needs, especially in diseases associated with innate immunity. The company is building its product pipeline through in-licensing and internal research. Its product development pipeline includes two drug candidates for treating type II diabetes, arthritis, and immunodermatology diseases and others. Itâs still in the research and development stage, its operating income is the contract revenue from the signing of the contract with the Castal Creek Pharmaceuticals (CCP) about its drug AC-203 for the treatment of epidermolysis bullosa (EB). It mainly aims at America market.
| 1st Jan change | Capi. | |
|---|---|---|
| -7.86% | 35.28M | |
| +29.03% | 48.16B | |
| -0.10% | 41.73B | |
| +43.45% | 41.03B | |
| -5.26% | 28.77B | |
| +11.48% | 25.59B | |
| -22.74% | 18.96B | |
| +9.06% | 12.92B | |
| +30.01% | 12.03B | |
| -1.51% | 11.77B |
- Stock Market
- Equities
- 6610 Stock
